These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32427578)

  • 1. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
    Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
    J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innate RIG-I signaling restores antigen presentation in tumors and overcomes T cell resistance.
    Thier B; Paschen A
    Cell Stress; 2021 Jan; 5(2):26-28. PubMed ID: 33554047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
    Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
    EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma.
    Li Y; Song Y; Li P; Li M; Wang H; Xu T; Yu X; Yu Y; Tai Y; Chen P; Cai X; Wang X; Xiang L; Deng R; Zhang X; Gao L; Wang X; Liu J; Cao F
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RIG-I activation is critical for responsiveness to checkpoint blockade.
    Heidegger S; Wintges A; Stritzke F; Bek S; Steiger K; Koenig PA; Göttert S; Engleitner T; Öllinger R; Nedelko T; Fischer JC; Makarov V; Winter C; Rad R; van den Brink MRM; Ruland J; Bassermann F; Chan TA; Haas T; Poeck H
    Sci Immunol; 2019 Sep; 4(39):. PubMed ID: 31519811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
    Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
    J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
    Huang F; Gonçalves C; Bartish M; Rémy-Sarrazin J; Issa ME; Cordeiro B; Guo Q; Emond A; Attias M; Yang W; Plourde D; Su J; Gimeno MG; Zhan Y; Galán A; Rzymski T; Mazan M; Masiejczyk M; Faber J; Khoury E; Benoit A; Gagnon N; Dankort D; Journe F; Ghanem GE; Krawczyk CM; Saragovi HU; Piccirillo CA; Sonenberg N; Topisirovic I; Rudd CE; Miller WH; Del Rincón SV
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33690225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
    Hu Z; Xia J; Fan W; Wargo J; Yang YG
    Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.
    Maciag PC; Seavey MM; Pan ZK; Ferrone S; Paterson Y
    Cancer Res; 2008 Oct; 68(19):8066-75. PubMed ID: 18829565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
    Ruzicka M; Koenig LM; Formisano S; Boehmer DFR; Vick B; Heuer EM; Meinl H; Kocheise L; Zeitlhöfler M; Ahlfeld J; Kobold S; Endres S; Subklewe M; Duewell P; Schnurr M; Jeremias I; Lichtenegger FS; Rothenfusser S
    Leukemia; 2020 Apr; 34(4):1017-1026. PubMed ID: 31740809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas.
    Sari G; Dhatchinamoorthy K; Orellano-Ariza L; Ferreira LM; Brehm MA; Rock K
    J Exp Clin Cancer Res; 2024 Oct; 43(1):276. PubMed ID: 39354629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-Methyladenosine Modification Controls Circular RNA Immunity.
    Chen YG; Chen R; Ahmad S; Verma R; Kasturi SP; Amaya L; Broughton JP; Kim J; Cadena C; Pulendran B; Hur S; Chang HY
    Mol Cell; 2019 Oct; 76(1):96-109.e9. PubMed ID: 31474572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling.
    Peng D; Chen L; Sun Y; Sun L; Yin Q; Deng S; Niu L; Lou F; Wang Z; Xu Z; Wang C; Fan L; Wang H; Wang H
    Biomed Pharmacother; 2020 May; 125():109984. PubMed ID: 32066042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
    Bullock TN; Mullins DW; Colella TA; Engelhard VH
    J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.
    Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X
    Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.